In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Conjugate Pegvisomant | Natural peptide IGF-1 (mecasermin) | |
|---|---|---|---|
| Identity | |||
| Kind | Conjugate | Natural peptide | |
| Area | Growth hormone axis | Growth hormone axis | |
| Evidence | |||
| Amount of evidence | 299 | 415 (plus 6 on natural levels, listed separately) | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 12 (12 in people) | 55 (55 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 37 · 1 active4 more mention it but do not test it | 52 · 3 active254 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Somavert says: “Acromegaly in patients with an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Pegvisomant | IGF-1 (mecasermin) |
|---|---|---|
| Growth hormone and IGF-1Metabolic and weight | 13111021 | 65548 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Increlex says: “Growth failure in children aged 2 years and older with severe primary IGF-1 deficiency, or GH gene deletion with neutralizing antibodies to GH”
| Glycemic controlMetabolic and weight | 2626 | 7474 |
|---|
| Adverse eventsWhole body | 1212 | 4646 |
|---|
| Bone and jointMusculoskeletal | 1147 | 52502 |
|---|
| PharmacokineticsPharmacology | 1313 | 3131 |
|---|
| LipidsMusculoskeletal | 1919 | 1111 |
|---|
| Protein and amino acid metabolismMetabolic and weight | 11 | 1818 |
|---|
| Muscle injury and repairMusculoskeletal | 33 | 1414 |
|---|
| Sex hormones and fertilityReproductive and sexual health | 22 | 1212 |
|---|
| Exercise and physical functionMusculoskeletal | 33 | 66 |
|---|
| Body weightMetabolic and weight | 11 | 1082 |
|---|
| Quality of lifeWhole body | 77 | 11 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Pegvisomant differs from Human growth hormone at 9 positions.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Pegvisomant | IGF-1 (mecasermin) |
|---|---|---|
| Bone and jointMusculoskeletalCompared as: difference from placebo, in p value | No comparable result 3 randomized-trial results measure it in another way or another unit. | 0.05 P value P value for spinal bone density change comparison Dose studied: 30 microg/kg twice daily9 monthsn = 602002 |
| Growth hormone and IGF-1Metabolic and weightCompared as: difference from placebo, in % | −34% Total IGF-I reduction · Shown as a change. The study reports a total igf-i reduction of this size. Dose studied: 1 mg/kg, single injectionn = 162002 | |
| LipidsMetabolic and weightCompared as: value in the arm that got the peptide, in micromol/liter | 1074 micromol/liter Free fatty acids Saline: 1226 micromol/liter n = 102009 | No comparable result 2 randomized-trial results measure it in another way or another unit. |
| Glycemic controlMetabolic and weightCompared as: difference from placebo, in unitless | No comparable result 12 randomized-trial results measure it in another way or another unit. | −0.03 unitless P value for HbA1c reduction versus placebo · Shown as a change. The study reports a p value for hba1c reduction versus placebo of this size. Dose studied: 40 microg/kg daily24 weeksn not reported1997 |
| Muscle injury and repairMusculoskeletalCompared as: value in the arm that got the peptide, in % | No comparable result 3 randomized-trial results measure it in another way or another unit. | 4.5% Whole-body protein synthesis increase · low-dose rhIGF-I 0.015 mg/kg twice daily Dose studied: 0.015 mg/kg twice daily1 mon not reported1997 |
No comparable result
3 randomized-trial results measure it in another way or another unit.
0.05 P value
P value for spinal bone density change comparison
Dose studied: 30 microg/kg twice daily9 monthsn = 602002
No comparable result
6 randomized-trial results measure it in another way or another unit.
−34%
Total IGF-I reduction · Shown as a change. The study reports a total igf-i reduction of this size.
Dose studied: 1 mg/kg, single injectionn = 162002
No comparable result
6 randomized-trial results measure it in another way or another unit.
1074 micromol/liter
Free fatty acids
Saline: 1226 micromol/liter
n = 102009
No comparable result
2 randomized-trial results measure it in another way or another unit.
No comparable result
12 randomized-trial results measure it in another way or another unit.
−0.03 unitless
P value for HbA1c reduction versus placebo · Shown as a change. The study reports a p value for hba1c reduction versus placebo of this size.
Dose studied: 40 microg/kg daily24 weeksn not reported1997
No comparable result
3 randomized-trial results measure it in another way or another unit.
4.5%
Whole-body protein synthesis increase · low-dose rhIGF-I 0.015 mg/kg twice daily
Dose studied: 0.015 mg/kg twice daily1 mon not reported1997
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 37 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Ipsen125 participantsOct 2006 to Oct 2008
Acromegaly
Novartis Pharmaceuticals70 participantsSept 2006 to Nov 2009
Acromegaly
Vanderbilt University44 participantsJan 2013 to May 2017
Obesity
4 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 52 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
The University of Texas Medical Branch, Galveston644 participantsJul 2000 to Apr 2013
Burns
Mayo Clinic330 participantsJun 2003 to Dec 2007
Amyotrophic Lateral Sclerosis
Ipsen137 participantsMar 2004 to Jul 2008
Growth Disorders · Insulin-Like Growth Factor-1 Deficiency
254 more mention it but do not test it. They only measure it or name it in their text.